

Press release

SYNLAB International GmbH

Moosacher Straße 88

80809 Munich

Germany

Munich, 16 July 2020

SYNLAB and Microba sign strategic agreement to launch advanced gut microbiome test MyBiome into Europe and LATAM

- SYNLAB and Microba combine their expertise to produce MyBiome.
- MyBiome is an innovative gut microbiome examination based on the expertise of, and technology developed by, leading researchers in the field of microbiome analysis.
- The combination of world-leading whole-genome metagenomic sequencing and evidence-based reporting provides a comprehensive picture of the gut microbiome.
- It uses an objective analysis of the make-up of an individual's gut microbiome and its metabolic potential to deliver personalized and actionable recommendations to improve health.
- Release in Spain and Colombia in 2020 with extended launch throughout Europe and LATAM to be considered in 2021.

SYNLAB, the leading medical diagnostic services provider in Europe, and Microba, world leader in the analysis of complex gut microbiomes, have signed a strategic agreement to launch the gut microbiome test MyBiome in Europe and LATAM. MyBiome will be an innovative and one of the most comprehensive metagenomic sequence-based tests available in the market, allowing an objective and actionable analysis of an individual's gut microbiome.

MyBiome analyses the community of microorganisms in the gut and what is scientifically known about their role in contributing to health. It is evidence-based and details the bacterial species in the gut microbiome and evaluates their functional potential compared to local healthy reference ranges, to deliver personalised recommendations to improve health.

Microba's award winning Metagenomic Analysis Platform (MAP™) comprising proprietary sampling technology and next-generation sequencing assay, analyses the genomes of the community of organisms living in the gut. The technology has been built from more than 20 years of research and experience to enable a depth of information and analysis that has not previously been accessible. This focus on comprehensive analysis and personalised interpretation is what makes MyBiome stand out in the market.



Release of the product will commence with a pilot phase in Spain and Colombia in 2020, with broader product launch throughout Europe and LATAM to be considered in 2021.

“We are excited to start this collaboration with Microba. SYNLAB’s commitment to medical excellence in diagnostics is underlined by complementing our test portfolio with the MyBiome analysis”, says Dr Santiago Valor, Chief Medical Officer of SYNLAB Group. “Together we set a sign for continuous medical advancement to the benefit of patients and customers.”

“SYNLAB is a global leader in delivering medical diagnostic services and we are proud to be partnering to add advanced gut microbiome testing to their portfolio, powered by Microba’s technology”, commented Blake Wills, CEO of Microba. “Microba’s partnership with SYNLAB enables us to expand the reach of our technology into the European and LATAM market to provide a complete picture of the gut microbiome, an important component of our health.

– Ends –

For more information:

SYNLAB Daniel Herbert, FTI Consulting	+49 (0) 69 9203 7183 Daniel.Herbert@fticonsulting.com
---	---

About SYNLAB

SYNLAB Group is the leading medical diagnostic services provider in Europe. SYNLAB offers a full range of innovative and reliable medical diagnostics for patients, practising doctors, clinics and the pharmaceutical industry.

Providing the leading level of service within the industry, SYNLAB is the partner of choice for healthcare professionals. SYNLAB’s services also encompass veterinary and environmental laboratory analysis.

SYNLAB operates in more than 40 countries across four continents and holds leading positions in most markets. Over 20,000 employees contribute every day to the Group’s world-wide success. SYNLAB carries out 500 million laboratory tests per year, achieving sales revenues of more than EUR 2.1 billion.

More information can be found on www.synlab.com

About Microba

Microba is a world-leading microbial genomics company that provides customers with access to cutting-edge technology to analyze the gut microbiome.

Microba’s advanced metagenomics technology and proprietary bioinformatics pipeline, provides practitioners and their patients with a deeper understanding of the gut microbiome to improve healthcare. Microba originated out of technology developed at The University of Queensland by co-founders and pioneers in the analysis of metagenomics data, Professor Phil Hugenholtz and Professor Gene Tyson. With a world-class laboratory and industry leading bioinformatic processes, Microba is a leader in the development of new clinical services, therapeutics and diagnostics based on the microbiome.